102 reports of this reaction
1.3% of all DEXMETHYLPHENIDATE HYDROCHLORIDE reports
#20 most reported adverse reaction
SUICIDAL IDEATION is the #20 most commonly reported adverse reaction for DEXMETHYLPHENIDATE HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 102 FDA adverse event reports linking DEXMETHYLPHENIDATE HYDROCHLORIDE to SUICIDAL IDEATION. This represents approximately 1.3% of all 7,728 adverse event reports for this drug.
Patients taking DEXMETHYLPHENIDATE HYDROCHLORIDE who experience suicidal ideation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDAL IDEATION is a less commonly reported adverse event for DEXMETHYLPHENIDATE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to suicidal ideation, the following adverse reactions have been reported for DEXMETHYLPHENIDATE HYDROCHLORIDE:
The following drugs have also been linked to suicidal ideation in FDA adverse event reports:
SUICIDAL IDEATION has been reported as an adverse event in 102 FDA reports for DEXMETHYLPHENIDATE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDAL IDEATION accounts for approximately 1.3% of all adverse event reports for DEXMETHYLPHENIDATE HYDROCHLORIDE, making it a notable side effect.
If you experience suicidal ideation while taking DEXMETHYLPHENIDATE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.